查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571491

DNA/RNA 银行服务市场规模、份额、趋势分析报告：按服务、检体、应用、最终用途和细分市场进行预测，2024-2030 年

DNA & RNA Banking Services Market Size, Share & Trends Analysis Report By Service, By Specimen (Blood, Buccal Swabs & Hair Follicles, Others), By Application, By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

DNA/RNA 银行服务市场的成长与趋势：

根据 Grand View Research, Inc. 的最新报告，预计 2030 年全球 DNA 和 RNA 银行服务市场规模将达到 109.2 亿美元，2024 年至 2030 年复合年增长率为 5.5%。

储存 DNA 和 RNA 等人类生物资源的设施对于生物标记的发现至关重要，并为个人化医疗的扩展铺平了道路。此外，透过引入先进和标准化的细胞分离技术，转化和临床研究的进步将减少工作时间。自动化解决方案和生物样本库全自动化的开拓可能会加速市场成长。

个人化医疗倡议的个人註册人数的增加将推动 DNA 和 RNA 银行服务的收益。 2019 年 7 月，Partners Healthcare（美国）在其精准医疗生物库中招募了超过 10 万人，该生物库为布莱根妇女医院（美国）和其他合作伙伴的临床医生和研究人员提供支援。这些努力有助于研究多种因素对疾病和健康的影响。

分销网络不断变得更加复杂，製药公司面临着与永续性工作、监管合规性以及竞争优先事项带来的成本压力相关的新挑战。主要企业在不同地区投资低温运输仓储和扩大分销能力的努力提高了它们处理大量复杂低温运输生技药品的能力。 EasyDNA、DNA Genotek、23andMe、GoodCell、ProteoGenex.、 美国 Biolab 等主要企业已采取多个策略联盟来增加其在市场上的影响力。

DNA/RNA 银行服务市场报告亮点

  • 按服务类型划分，2023年储存服务占销售额的最大份额。自动化样品储存系统和自动化液体处理机的出现进一步推动了这一领域的发展，这些系统和自动化液体处理机可以管理大量样品并减少处理、储存和分发样品所需的时间。
  • 从检体类型来看，血液检体由于采血速度快、时间短、污染风险最小以及血液检体的可见度高，在2023年占据市场主导地位。
  • 从应用来看，2023年药物发现和临床研究领域占最大。生物银行服务将为加速新疗法的发现和未来研究更好地了解环境、遗传和生活方式因素对人类健康、发病率和死亡率的影响提供资源。这些因素导致该细分市场的收益占有率最大。
  • 根据最终用途，在政府机构和生物银行努力扩大医院和诊断中心用于 COVID-19 诊断的 DNA 和 RNA 样本的推动下，医院和诊断中心细分市场将在预测期内继续增长。的增长。
  • 2023 年，北美地区的收益占有率最大。积极加速市场成长的主要因素之一是美国「All of Us」生物库等国家精准医疗措施的启动。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 DNA/RNA 银行服务市场的变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 产业分析-波特五力分析
    • 供应商的力量
    • 买家的力量
    • 另类威胁
    • 新进入的威胁
    • 竞争公司之间的敌对关係
  • PESTEL分析
    • 政局
    • 技术景观
    • 经济状况

第四章 DNA/RNA银行服务市场：服务评估与趋势分析

  • 细分仪表板
  • DNA/RNA 银行服务市场：2023 年和 2030 年服务变化分析
  • 交通服务
  • 加工服务
  • 仓储服务
  • 品管服务
  • 资料储存
  • 其他的

第五章 DNA/RNA银行服务市场：检体估计与趋势分析

  • 细分仪表板
  • DNA/RNA 银行服务市场：检体变异分析，2023 年和 2030 年
  • 血
  • 颊黏膜拭子和毛囊
  • 其他的

第六章 DNA/RNA 银行服务市场：使用量估计与趋势分析

  • 细分仪表板
  • DNA/RNA 银行服务市场：2023 年和 2030 年应用变化分析
  • 治疗药物
    • 2018年至2030年市场预测
  • 药物发现与临床研究
    • 2018年至2030年市场预测
  • 临床诊断
    • 2018年至2030年市场预测
  • 其他用途
    • 2018年至2030年市场预测

第七章 DNA/RNA 银行服务市场：最终用途估计与趋势分析

  • 细分仪表板
  • DNA/RNA 银行服务市场：最终用途变化分析，2023 年和 2030 年
  • 学术研究
  • 製药和生物技术公司
  • 医院和诊断中心
  • 其他的

第八章 DNA/RNA银行服务市场：区域估算与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场简介
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
  • 公司简介
    • EasyDNA
    • DNA Genotek Inc.
    • 23andMe, Inc.
    • GoodCell
    • ProteoGenex
    • US Biolab Corporation, Inc.
    • Infinity Biologix
    • Thermo Fisher Scientific, Inc.
    • deCODE genetics
    • AG Brooks Life Sciences
    • LGC Biosearch Technologies
    • PreventionGenetics
简介目录
Product Code: GVR-4-68039-325-9

DNA & RNA Banking Services Market Growth & Trends:

The global DNA & RNA banking services market size is expected to reach USD 10.92 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Biospecimens such as DNA and RNA are critical for biomarker discovery, thereby providing a path for the expansion of personalized medicine. Moreover, progress in translational and clinical research through an introduction of advanced, standardized cell isolation methodologies reduces hands-on-time. The development of automated solutions and the transformation of biobanks into fully automated biobanks potentially accelerate the growth of the market.

A rise in the enrollment of individuals for personalized medicine initiatives drives the revenue generation for DNA and RNA banking services. In July 2019, Partners HealthCare, U.S. enrolled more than 100,000 individuals in its precision medicine biobank that supported clinicians and researchers of the Brigham and Women's Hospital, U.S., and other partners. Such initiative assisted in examining the impact of several factors on disease and health.

The distribution network is continuously becoming complex, with pharmaceutical firms facing new challenges related to sustainability initiatives, regulatory adherence, and competing priorities cost pressures. The efforts undertaken by the key players to invest in the cold chain storage and expansion of distribution capability in various geographies have increased the capability to handle large quantities of complex cold chain biologics. Key companies such as EasyDNA, DNA Genotek, 23andMe, GoodCell, ProteoGenex., and US Biolab have adopted several strategic alliances to reinforce their market presence.

DNA & RNA Banking Services Market Report Highlights:

  • By service type, storage services accounted for the largest revenue share in 2023 owing to the presence of numerous key providers in the market space. The advent of automated sample storage systems and automated liquid handlers to manage large sample volume, and reduce the amount of time required to process, store, and distribute samples further drives the segment
  • Based on specimen type, the blood segment dominated the market in 2023 owing to fast and quick procedures of collecting blood, minimal risk of contamination, and visibility of blood samples
  • In terms of application, the drug discovery and clinical research segment held the largest share in 2023. Biobanking services are utilized to accelerate the discovery of new therapeutics and offer resources for future investigations to better understand the effects of environmental, genetic, and lifestyle factors on human health, morbidity, and mortality. This factor led to the maximum revenue share of the segment
  • On the basis of end use, the hospitals and diagnostic centers segment is projected to witness the fastest growth throughout the forecast period owing to the efforts undertaken by government bodies and biobanks to broaden the accessibility for DNA and RNA samples in the hospitals and diagnostic centers for COVID-19 diagnosis
  • North America accounted for the largest revenue share in 2023. One of the major factors positively accelerating market growth is the initiation of national precision-medicine initiatives, such as the "All of Us" biobank in the U.S.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. DNA & RNA Banking Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Industry Analysis - Porter's
    • 3.3.1. Supplier power
    • 3.3.2. Buyer power
    • 3.3.3. Substitution threat
    • 3.3.4. Threat of new entrant
    • 3.3.5. Competitive rivalry
  • 3.4. PESTEL Analysis
    • 3.4.1. Political landscape
    • 3.4.2. Technological landscape
    • 3.4.3. Economic landscape

Chapter 4. DNA & RNA Banking Services Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. DNA & RNA Banking Services Market: Service Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Transportation Service
    • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4. Processing Service
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Storage Service
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Quality Control Service
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Data Storage
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. DNA & RNA Banking Services Market: Specimen Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. DNA & RNA Banking Services Market: Specimen Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Blood
    • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4. Buccal Swabs & Hair Follicles
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. DNA & RNA Banking Services Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. DNA & RNA Banking Services Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Therapeutics
    • 6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Drug Discovery & Clinical Research
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Clinical Diagnostics
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Other Applications
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. DNA & RNA Banking Services Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. DNA & RNA Banking Services Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Academic Research
    • 7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Pharmaceutical & Biotechnology Companies
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Hospitals & Diagnostic Centers
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. DNA & RNA Banking Services Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
  • 9.4. Company Profiles
    • 9.4.1. EasyDNA
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Service benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. DNA Genotek Inc.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Service benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. 23andMe, Inc.
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Service benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. GoodCell
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Service benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. ProteoGenex
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Service benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. US Biolab Corporation, Inc.
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Service benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Infinity Biologix
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Service benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Thermo Fisher Scientific, Inc.
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Service benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. deCODE genetics
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Service benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. AG Brooks Life Sciences
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Service benchmarking
      • 9.4.10.4. Strategic initiatives
    • 9.4.11. LGC Biosearch Technologies
      • 9.4.11.1. Company overview
      • 9.4.11.2. Financial performance
      • 9.4.11.3. Service benchmarking
      • 9.4.11.4. Strategic initiatives
    • 9.4.12. PreventionGenetics
      • 9.4.12.1. Company overview
      • 9.4.12.2. Financial performance
      • 9.4.12.3. Service benchmarking
      • 9.4.12.4. Strategic initiatives